Document is current
Any future updates will be listed below
-
Authors
Smorodina, Eva https://orcid.org/0000-0002-5457-5163
Diankin, Igor https://orcid.org/0000-0001-9206-5300
Tao, Fei https://orcid.org/0000-0002-5997-8770
Qing, Rui https://orcid.org/0000-0002-7952-2295
Yang, Steve https://orcid.org/0000-0002-5346-0321
Zhang, Shuguang https://orcid.org/0000-0002-3856-3752
- License Information
-
More Information
Article History
Received: 29 July 2022
Accepted: 4 November 2022
First Online: 22 November 2022
Competing interests
: Massachusetts Institute of Technology (MIT) filed several patent applications for the QTY code and OH2Laboratories licensed the technology specifically for G protein-coupled receptors from MIT. Shuguang Zhang is an inventor and has a minor equity of OH2Laboratories stock shares. MIT and Avalon GloboCare jointly filed a patent application for glucose transporters but did not file any patent application on the solute carrier transporters. After submitting the initial manuscript, Shuguang Zhang formed a startup 511 Therapeutics, Inc. in August 2022 to generate therapeutic monoclonal antibodies and holds majority equity. The PT Metiska Farma sponsored the study but had no influence and interference in the design of the study, in the data collection, analyses, or interpretation of data and in the writing of the manuscript, or in the decision to publish the results. All other authors have no competing interest.
